Skip to main content
SpringerLink
Log in

Hepatobiliary Cancer, Pancreatic Cancer, and Neuroendocrine Cancers of the Gastrointestinal Tract

  • Chapter
Oncologic Therapies

  • 147 Accesses

Abstract

Hepatocellular carcinoma (HCC or hepatoma) is one of the most common malignancies. Worldwide, the annual incidence is nearly 1 million and it causes an estimated 1,250,000 deaths every year. There is striking geographic variation, the highest rates being found in China, Southeast Asia, and sub-Saharan Africa (>20, and up to 100/100,000 males per year). The lowest rates (<5/100,000 males per year) are found in Northern Europe, North America, and Latin America [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics, 1996. CA 46:5–27

    PubMed  CAS  Google Scholar 

  2. Bosch FX, Munoz N (1991) Hepatocellular carcinoma in the world: epidemiological questions. In: Tabor E, DiBisceglie AM, Purcell RH (eds) Etiology, pathology, and treatment of hepatocellular carcinoma. Portfolio, The Woodlands, Texas, pp 1–10

    Google Scholar 

  3. Beasley RP (1988) Hepatitis B virus the major etiology of Hepatocellular carcinoma in the

    Google Scholar 

  4. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children; Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855–1859

    Article  PubMed  CAS  Google Scholar 

  5. Ross RK, Yuan JM, Yu MC et al (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339: 943–946

    Article  PubMed  CAS  Google Scholar 

  6. Brechot C (1998) Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 29:173–183

    Article  PubMed  CAS  Google Scholar 

  7. Ohtsuki T, Okuda K, Tomimatsu M et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 56:918–928

    Article  PubMed  Google Scholar 

  8. Johnson PJ (2001) Hepatocellular carcinoma. In: Prognostic factors in cancer, 2nd edn. UICC TNM Project and Prognostic Factors Committee. Dekker, New York

    Google Scholar 

  9. Tabor E, DiBisceglie AM, Purcell RH (eds) (1991) Etiology, pathology, and treatment of hepatocellular carcinoma in North America. Adv Appl Biotechnol Ser 13:504–514

    Google Scholar 

  10. Takayasu K, Furukawa H, Wakao F et al (1995) CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. Am J Roentgenol 164:885–890

    CAS  Google Scholar 

  11. Adson MA (1999) Primary hepatocellular cancers: western experience. In: Blumgart LH (ed) Surgery of the liver and biliary tract. Churchill-Livingstone, New York, pp 1155–1164

    Google Scholar 

  12. Pugh RHN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649

    Article  PubMed  CAS  Google Scholar 

  13. Romani F, Belli LS, Rondinara GF et al (1994) The role of transplantation in small hepatocellular carcinoma complicating cirrhosis of the liver. J Am Coll Surg 178:3779–3784

    Google Scholar 

  14. Venook AP, Stagg RJ, Lewis BJ et al (1990) Chemoembolization for hepatocellular carcinoma. J Clin Oncol 8:1108–1114

    PubMed  CAS  Google Scholar 

  15. Trinchet JC et al from Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261

    Article  Google Scholar 

  16. Castells A, Bruix J, Bru C et al (1993) Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injections. Hepatology 18:1121–1126

    PubMed  CAS  Google Scholar 

  17. Luporini G, Labianca R, Pancera G (1993) Medical treatment of hepatocellular carcinoma. J Surg Oncol [Suppl]3:115–118

    Article  Google Scholar 

  18. CLIP Group (no authors listed) (1998) Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 352:17–20

    Article  Google Scholar 

  19. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42:442–446

    Article  PubMed  CAS  Google Scholar 

  20. Ortega JA, Krailo MD, Haans JE (1991) Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion of doxorubicin chemotherapy: a report from the Children’s Cancer Study Group. J Clin Oncol 9:2167–2176

    PubMed  CAS  Google Scholar 

  21. Lai EC, Lo CM, Fan ST Liu CL, Wong J (1998) Postoperative chemotherapy after curative resection of hepatocellular carcinoma randomized trial. Arch Surg 133:183–188

    Article  PubMed  CAS  Google Scholar 

  22. Lau WY, Leung WT, Ho SKW et al (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797–801

    Article  PubMed  CAS  Google Scholar 

  23. Ho S, Lau WY, Leung TWT, Johnson PJ (1998) Internal radiation therapy for patients with primary or metastatic hepatic cancer. A review. Cancer 83:1894–1907

    Article  PubMed  CAS  Google Scholar 

  24. Lau WY, Ho S, Leung WT, Chan M, Ho R, Johnson PJ, Li AKC (1998) Selective internal radiation therapy for inoperable hepatocellular carcinoma with intraarterial infusion of yttrium90 microspheres. Int J Radiat Oncol Biol Phys 40: 583–592

    Article  PubMed  CAS  Google Scholar 

  25. Krain L (1972) Gallbladder and extrahepatic bile duct carcinoma: analysis of 1808 cases. Geriatrics 27:1111–1117

    Google Scholar 

  26. Altaee MY, Johnson PJ, Farrant JM et al (1991) Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 68:2051–2055

    Article  PubMed  CAS  Google Scholar 

  27. Schoenthaler R, Philips TL, Castro J et al (1994) Carcinoma of the extrahepatic bile ducts: the University of California at San Francisco experience. Ann Surg 219:267–272

    Article  PubMed  CAS  Google Scholar 

  28. Mani S, Sciortino D, Samuels B, Arrietta R, Schilsky RL, Vokes EE, Benner S (1999) Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs 17:97–101

    Article  PubMed  CAS  Google Scholar 

  29. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183–186

    Article  PubMed  CAS  Google Scholar 

  30. Sanz-Altamira PM, O’Reilly E, Stuart KE, Raeburn L, Steger C, Kemeny NE, Saltz LB (2001) A phase II trail of irinotecan (CPT-11) for unresectable biliary tract carcinoma. Ann Oncol 12:501–504

    Article  PubMed  CAS  Google Scholar 

  31. Matsubara T, Funabiki T, Jinno O, Sakurai Y, Hasegawa S, Imazu H, Ochiai M (1999) p53 gene mutations and overexpression of p53 product in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. J Hepat Pancreat Surg 6:286–293

    Article  CAS  Google Scholar 

  32. Fiorentino M, D’Errico A, Altimari A, Barozzi C, Grigioni WF (1999) High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas. Diagn Mol Pathol 8:189–194

    Article  PubMed  CAS  Google Scholar 

  33. Ahrendt SA, Rashid A, Chow JT, Eisenberger CF, Pitt HA, Sidransky D (2000) p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepat Pancreat Surg 7:426–431

    Article  CAS  Google Scholar 

  34. Baselga J (2000) Clinical trials of Herceptin(R) (trastuzumab). Eur J Cancer 37[Suppl l]:18–24

    Google Scholar 

  35. Boyle P, Hsieh CC, Maisonneuve P et al (1989) Epidemiology of pancreas cancer. Int J Pancreatol 5:327–346

    PubMed  CAS  Google Scholar 

  36. Lunch HT, Smyrk T, Kern SE et al (1996) Familial pancreatic cancer: a review. Semin Oncol 23:251–275

    Google Scholar 

  37. Durbec JP, Chevillotte C, Bidart JM et al (1983) Diet, alcohol, tobacco, and risk of cancer of the pancreas: a case-control study. Br J Cancer 43:463–470

    Article  Google Scholar 

  38. Norell SE, Ahlbom A, Erwald R et al (1986) Diet and pancreatic cancer: a case-control study. Am J Epidemiol 124: 894–902

    PubMed  CAS  Google Scholar 

  39. Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455–456

    Article  PubMed  CAS  Google Scholar 

  40. Ghadirian P, Simard A, Baillargeon J (1991) Tobacco, alcohol, and coffee and cancer of the pancreas. Cancer 67:2664–2670

    Article  PubMed  CAS  Google Scholar 

  41. American Joint Committee on Cancer (1997) AJCC cancer staging manual, 5th edn. American Cancer Society, Lippincott-Raven, Philadelphia

    Google Scholar 

  42. NCCN (1997) NCCN practice guidelines for pancreatic cancer. NCCN oncology practice guidelines. Oncology 11: 41–55

    Google Scholar 

  43. Yeo CJ, Cameron JL, Lillemoe KD et al (1997) Pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928–937

    Google Scholar 

  44. Moertel CG, Reitemeier RJ (1969) Advanced gastrointestinal cancer — clinical management and chemotherapy. Hoeber, Medical Division, Harper and Row, New York, p 7–42

    Google Scholar 

  45. Moertel CG, Childs DS, Reitemeier RJ et al (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867

    Article  PubMed  CAS  Google Scholar 

  46. Haslam JB, Cavanaugh PJ, Stroup SL (1973) Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 32:1341–1345

    Article  PubMed  CAS  Google Scholar 

  47. Thomas PRM (1996) Radiotherapy for carcinoma of the pancreas. Semin Oncol 23:213–219

    PubMed  CAS  Google Scholar 

  48. Gastrointenstional Tumor Study Group (1985) Pancreatic ionther-fract ionated radiation and chemotherapy following curative resection. Arch Surg 120:899–903

    Article  Google Scholar 

  49. Gastrointestinal Tumor Study Group (1987) Effective surgicaladjuvant therapy for pancreatic cancer. Cancer 59: 2006–2110

    Article  Google Scholar 

  50. Sindelar WF, Kinsella TJ (1986) Randomized trial of intraoperative therapy in resected carcinoma of pancreas (abstract). Int J Radiat Oncol Biol Phys 12[Suppl 1]:148

    Article  Google Scholar 

  51. Whittington R, Bryer MP, Haller DG et al (1991) Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 21:1137–1143

    Article  PubMed  CAS  Google Scholar 

  52. Klinkenbijl JH, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection for the cancer of the pancreas abd peri-ampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776–784

    Article  PubMed  CAS  Google Scholar 

  53. Neoptolemos JP, Dunn JA, Moffitt DD et al (2000) ESPAC-1 interim results: European randomized study to assess the roles of adjuvant chemotherapy (5-FU + folinic acid) and adjuvant chemoradiation (40 Gy + 5-FU) in resectable pancreatic cancer (abstract no. 923). Proc Am Soc Clin Oncol 19:238A

    Google Scholar 

  54. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA, Evans DB (1997) Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928–937

    PubMed  CAS  Google Scholar 

  55. Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB (1998) Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16:3843–3850

    PubMed  CAS  Google Scholar 

  56. Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, Jinnah R, Evans DB (1997) Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 226:632–641

    Article  PubMed  CAS  Google Scholar 

  57. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB III (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16:317–323

    PubMed  CAS  Google Scholar 

  58. Gastrointestinal Tumor Study Group (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000rads) radiation alone, moderate radiation (4000rads) plus 5-fluorouracil and high dose radiation plus 5-fluorouracil. Cancer 58:1705–1710

    Google Scholar 

  59. Gastrointestinal Tumor Study Group (1985) Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of cally unresectable pancreatic carcinoma: Cancer 56:2563–2568

    Article  Google Scholar 

  60. Seydel HG, Stabilem DM, Leichman LP et al (1990) Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group Experience. Cancer 65: 1478–1482

    Article  PubMed  CAS  Google Scholar 

  61. Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80: 751–755

    Article  Google Scholar 

  62. Treurniet-Donker AD, Van Mierlo MJM, Van Putten WLJ (1990) Localized unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 18:59–62

    Article  PubMed  CAS  Google Scholar 

  63. Komaki R, Wadler S, Peters T et al (1992) High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. Cancer 69:2807–2812

    Article  PubMed  CAS  Google Scholar 

  64. Bornman PC, Harris-Jones EP, Tobias R et al (1986) Prospective controlled trial of transhepatic biliary endoprothesis versus bypass surgery for incurable carcinoma of head of pancreas. Lancet 1:69–71

    Article  PubMed  CAS  Google Scholar 

  65. Schnall SF, Macdonald JS (1996) Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23:220–228

    PubMed  CAS  Google Scholar 

  66. Schultz RM (1995) Future directions for the treatment of human pancreatic carcinoma. Exp Opin Invest Drug 4: 1273–1279

    Article  Google Scholar 

  67. Mallinson CN, Rake MO, Cocking JB et al (1980) Chemotherapy in pancreatic cancer: results of a controlled prospective, and randomised, multicentre trial. Br Med J 281: 1589–1591

    Article  PubMed  CAS  Google Scholar 

  68. Cullinan S, Moertel CG, Wieand HS et al (1990) A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 65:2207–2212

    Article  PubMed  CAS  Google Scholar 

  69. The Gastrointestinal Tumor Study Group (1986) Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozotocin plus mitomycin-C plus fluorouracil. J Clin Oncol 4:1794–1798

    Google Scholar 

  70. Burris HA III, Moore Malcolm J, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  71. Tempero M, Plunkett W, Haperen VR, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (1999) Randomised phase II trial of dose intense gemcitabine by standard infusion versus fixed dose rate in metastatic pancreatic adenocarcinoma (abstract no. 1048). Proc Am Soc Clin Oncol 18: 273A

    Google Scholar 

  72. Butera J, Malachovsky M, Rathore R, Safran H (1998) Novel approaches in development for the treatment of pancreatic cancer. Front Biosci 3:E226–E229

    PubMed  CAS  Google Scholar 

  73. Buchler P, Reber HA, Buchler MC, Roth MA, Buchler MW, Friess H, Isacoff WH, Hines OJ (2001) Therapy for pancreatic cancer with a recombinant humanized anti-her2 antibody (Herceptin). J Gastrointest Surg 5:139–146

    Article  PubMed  CAS  Google Scholar 

  74. Bramhall SR (1997) The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Int J Pancreatol 21:1–12

    PubMed  CAS  Google Scholar 

  75. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 8:308–315

    Article  PubMed  CAS  Google Scholar 

  76. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O’Reilly S, Abrams RA, Pardoll DM, Cameron JL, Yeo CJ (2001) Novel allogeneic granulocytemacrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19:145–156

    PubMed  CAS  Google Scholar 

  77. Van Riel JM, Giaccone G, Pinedo HM (1999) Pancreaticobiliary cancer: the future aspects of medical oncology. Ann Oncol 10[Suppl 4]:296–299

    PubMed  Google Scholar 

  78. Moertel CG (1987) An Odyssey in the land of small tumors. J Clin Oncol 5:1503–1522

    Google Scholar 

  79. Larsson C, Shogseid B, Oberg K et al (1988) MEN-1 gene maps to chromosome 11 and is lost in insuloma. Nature 332:85–87

    Article  PubMed  CAS  Google Scholar 

  80. Wilander E (1989) Diagnostic pathology of gastrointestinal pancreatic neuroendocrine tumors. Acta Oncol 288:363–369

    Article  Google Scholar 

  81. Waltenberger J, Lundin L, Oberg K et al (1993) Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 142:71–78

    PubMed  CAS  Google Scholar 

  82. Chaudhry A, Gobl A, Eriksson B et al (1994) Different splice variance of CD44 are expressed in gastrinomas but not in other subtypes or endocrine pancreatic tumors. Cancer Res 54:981–986

    PubMed  CAS  Google Scholar 

  83. Maton PN (1988) The carcinoid syndrome. JAMA 260: 1602–1605

    Article  PubMed  CAS  Google Scholar 

  84. Maartensson H, Norbin A, Bengmarks S et al (1984) Embolization of the liver in the management of metastatic carcinoid tumors. J Surg Oncol 27:152–158

    Article  Google Scholar 

  85. Kvols LK, Moertel CG, O’Connell MJ et al (1986) Treatment of malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663–666

    Article  PubMed  CAS  Google Scholar 

  86. Oberg K, Norheim I, Lind E (1986) Treatment of malignant carcinoid tumors with human leukocyte interferon: longterm results. Cancer Treat Rep 70:1297–1304

    PubMed  CAS  Google Scholar 

  87. Legha SS, Valdivieso M, Nelson RS et al (1977) Chemotherapy for metastatic carcinoid tumors: experience with 32 patients and a review of the literature. Cancer Treat Rep 61: 1699–1703

    PubMed  CAS  Google Scholar 

  88. Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G (2001) Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology 60:141–145

    Article  PubMed  CAS  Google Scholar 

  89. Pathirana AA, Vinjamuri S, Byrne C, Ghaneh P, Vora J, Poston GJ (2001) 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol 27:404–408

    Article  PubMed  CAS  Google Scholar 

  90. McCarthy KE, Woltering EA, Anthony LB (2000) In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives (review). Q J Nucl Med 44:88–95

    PubMed  CAS  Google Scholar 

  91. Ajani JA, Kegha SS, Karlin DA et al (1983) Combination chemotherapy of metastatic carcinoid tumors with 5-FU, Adriamycin, and Cytoxan (FAX) and 5-FU, Adriamycin, mitomycin-C, and methyl CCNU (FAMMe) (abstract). Proc Am Soc Clin Oncol 2:124

    Google Scholar 

  92. Kissinger A, Foley FJ, Lemon JH (1977) Use of DTIC (dacarbazine) in the malignant carcinoid tumors. Cancer Treat Rep 61:101–102

    Google Scholar 

  93. Moertel CG, Kvols LK, O’Connell MJ et al (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227–232

    Article  PubMed  CAS  Google Scholar 

  94. Jensen RT, Gardner JD (1991) Zollinger-Ellison syndrome: clinical presentation, pathology, diagnosis and treatment. In: Dannenberg A, Zakim D (eds) Peptic ulcer and other acid-related diseases. Academic Research Association, New York, pp 117–131

    Google Scholar 

  95. Malagelada JR, Edis AJ, Adson MA et al (1983) Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 84:1524–1532

    PubMed  CAS  Google Scholar 

  96. Norton JA, Doppman JL, Jensen RT (1992) Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg 215:218

    Google Scholar 

  97. Jensen RT, Norton JA (1995) Endocrine tumors of the pancreas. In: Yamada T, Alpers BH, Owyang C et al (eds) Textbook of gastroenterology. Lippincott, Philadelphia, p 2131–2140

    Google Scholar 

  98. Doppmann J (1992) Pancreatic endocrine tumors — the search goes on (editorial). N Engl J Med 326:1770–1772

    Article  Google Scholar 

  99. Verner JV, Morrison AB (1958) Islet cell tumor and a syndrome refractory watery diarrhea and hypokalemia. Am J Med 25:375–380

    Article  Google Scholar 

  100. Moertel CG, Hahnley JA, Johnsson LA (1980) Streptozocin alone compared with streptozocin plus fiuorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 303:1189–1193

    Article  PubMed  CAS  Google Scholar 

  101. Moertel CG, Lefkopoulos M, Lipsitz S et al (1992) Streptozocin, doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 326:519–523

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. Mani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. J. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Chicago, Medical Center, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, 60637-1470, USA

    Everett E. Vokes M.D.  & Harvey M. Golomb M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mani, S., Johnson, P.J. (2003). Hepatobiliary Cancer, Pancreatic Cancer, and Neuroendocrine Cancers of the Gastrointestinal Tract. In: Vokes, E.E., Golomb, H.M. (eds) Oncologic Therapies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55780-4_34

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-55780-4_34

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62818-4

  • Online ISBN: 978-3-642-55780-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation